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In this issue of Cancer Cell, Finley and coworkers report that the genetic loss of the deacetylase SIRT3 leads
to metabolic reprogramming toward glycolysis. This shift is mediated by an increase in cellular reactive
oxygen species (ROS) generation that amplifies HIF-a stabilization and HIF-dependent gene expression,
thereby driving the tumor phenotype.In cancer cells, reprogramming of cellular
metabolism drives substrate utilization
toward a dependence on glucose.
First described by Otto Warburg (War-
burg, 1956), the significance of this
response for tumor growth has been
controversial. However, it appears that
this glycolytic shift is necessary to
provide a source of substrates for the
synthesis of amino acid, lipids, and
nucleic acids that are needed for prolifer-
ation (Vander Heiden et al., 2009).
Indeed, enhanced glucose uptake by
tumor cells forms the basis for the clinical
detection of tumors by imaging regions
exhibiting increased uptake of the
glucose analog 18F-fluordeoxyglucose.
While the association between cancer
and the Warburg metabolic shift is well
established, the cellular mechanisms
regulating this response are not fully
understood.
Posttranslational modifications of pro-
teins are important for regulating their
function in health and disease. Critical
roles for protein deacetylases are alsoemerging in cancer. For example, Kim
et al. (2010) identified a role for SIRT3,
a member of the seven-member sirtuin
family, as a tumor suppressor. They
showed that genetic deletion of SIRT3
pushes the cell in the direction of onco-
genic transformation. While activation of
two oncogenes (such as Myc and Ras)
is needed to transform an immortalized
fibroblast into a tumor-forming cell,
genetic deletion of SIRT3 reduced that
number to one. Thus, SIRT3 functions
as a tumor suppressor (Schumacker,
2010). The mechanistic basis for SIRT3’s
tumor-suppressive role seems to reside
in its ability to regulate reactive oxygen
species (ROS) generation or clearance
by the cell. Kim et al. (2010) noted that
ROS levels were increased in SIRT3/
cells, as a consequence of a decreased
expression of antioxidant enzymes such
as catalase and MnSOD. The transcrip-
tion factor FOXO3a plays an important
role in regulating the expression
of MnSOD and other antioxidants,
and SIRT3-mediated deacetylation ofFOXO3a promotes its nuclear localization
(Jacobs et al., 2008). Thus, the loss of
SIRT3 activity suppresses FOXO3a,
leading to an increase in cellular ROS
signaling. Enhanced ROS levels have
been linked to cancer, and Kim et al.
(2010) observed an increase in the inci-
dence of mammary tumors in the SIRT3
knockout mice. They suggested that
the chronic increase in mitochondrial
ROS stress might result in mitochondrial
or genomic DNA damage, but that
mechanism was not directly tested.
Nevertheless, their study identified an
important pathway by which SIRT3
suppresses tumor cell survival and prolif-
eration through its effects on cellular ROS
regulation.
But even the best studies leave many
questions unanswered. The principal
issue left in the wake of the Kim et al.
(2010) study related to how the increase
inROS (causedby lossof SIRT3)mediates
the enhanced tumor phenotype of
cells. The answer to that question arrives
in the article by Finley et al. (2011) in this9, March 15, 2011 ª2011 Elsevier Inc. 299
Figure 1. Regulation of Tumor Cell Phenotype by SIRT3
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Previewsissue of Cancer Cell. While
confirming that the genetic
loss of SIRT3 leads to
an enhanced tumor pheno-
type in a ROS-dependent
manner, they move the field
forward in a profound way
by showing that this occurs
because the ROS enhance
HIF-1a stabilization. HIF-1
and HIF-2 are hypoxia-
responsive transcription fac-
tors that regulate the altered
expression of more than
200 genes in responses to
hypoxia (Semenza, 2010a).
Upregulation of HIF activity
is strongly linked to the
survival and proliferation of
tumor cells, because some
HIF-dependent genes such
as glucose transporters and
glycolytic enzymes, and
vascular endothelial growthfactor (VEGF) are critical for cell survival
when chronically exposed to a hypoxic
microenvironment in the tumor. Other
HIF-dependent genes affectmetabolic re-
programming, apoptosis, cell migration,
remodeling of the extracellular matrix,
iron metabolism, pH regulation, vascular
reactivity, and other functions that are inti-
mately involved in tumor progression and
metastasis (Semenza, 2010b). Finley
et al. (2011) made this connection by
comparing the gene expression profile in
brown adipose tissue of wild-type and
SIRT3 knockout mice, and noting that
the loss of SIRT3 led to a response that
mimicked the change when cells were
exposed to low oxygen. The mechanism
underlying the response to SIRT3 deletion
appears to involve an increase in ROS-
dependent inhibition of prolyl hydroxylase
(PHD) (Figure 1). This mechanism is
consistent with previous studies demon-
strating that mitochondrial ROS signals
regulate HIF-a stability in hypoxia (Chan-
del et al., 1998). Interestingly, the loss of
SIRT3, via enhanced HIF expression,300 Cancer Cell 19, March 15, 2011 ª2011 Emediates the Warburg shift in metabolism
in fibroblasts, driving them toward
enhanced glucose utilization that is
required for the enhanced growth proper-
ties they exhibit.
The loss of SIRT3 appears to drive HIF
activation even under basal normoxic
conditions, and to enhance the HIF
response to hypoxia through a ROS-
dependent mechanism. They report that
treatment of SIRT3 knockout cells with
the antioxidant N-acetyl cysteine (NAC) re-
turns the normoxic HIF to wild-type levels
while it abolishes the increased rate of
proliferation and metabolic reprogram-
ming. In vivo, NAC treatment repressed
the hypoxia-associated gene expression
profile in brown adipose tissue, without
affecting expression patterns in wild-type
animals. By contrast, overexpression of
SIRT3shifts thecell away fromtheWarburg
effect and suppresses the hypoxic
response, although the role of ROS in that
response was not directly investigated.
Impressively, Finley et al. (2011) go on
to provide correlative evidence showinglsevier Inc.an association between the
loss of SIRT3 in human breast
cancers and the enhanced
expression of HIF-1-depen-
dent genes. Whether or not
the loss of SIRT3 is a causa-
tive agent in cancer initiation
or whether subsequent loss
of SIRT3 in an existing
tumor cell helps to drive its
glycolytic and proliferative
phenotype are questions
that still need to be ad-
dressed. It seems likely that
both events may occur in
different conditions. In either
case, the finding that SIRT3
loss can enhance the HIF-de-
pendent response in cancer
opens therapeutic opportuni-
ties for drug targets while
it underscores the potential
importance of identifying
agents that can selectivelyinhibit ROS signaling and HIF activity in
cancer.
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